Defective Breast Mesh, Acellular Dermal Matrix, and Bioabsorbable Scaffold Injury Attorneys in Arkansas: The Complete Guide for Women, Families, and Survivors
For women across Arkansas—from the medical hubs of Little Rock and North Arkansas to the communities of the Delta and the Ozarks—the journey of breast reconstruction or aesthetic enhancement is one built on hope. Whether you are a survivor who walked through the doors of the UAMS Winthrop P. Rockefeller Cancer Institute for a life-saving mastectomy or a mother in Fayetteville seeking to restore your confidence after pregnancy, you trusted that the medical devices placed inside your body were safe. You trusted that the surgical mesh, acellular dermal matrix (ADM), or bioabsorbable scaffold reinforcement used to create your “internal bra” had been rigorously tested and approved for use in human breast tissue.
The truth we have uncovered is far more troubling. At The Manginello Law Firm, PLLC, operating as Attorney911, we have dedicated ourselves to exposing a regulatory failure that has left thousands of women in Arkansas and across the United States at risk. Many of the most common products used in breast procedures today—including GalaFLEX, Phasix, AlloDerm, and Strattice—entered the market through a regulatory shortcut known as the 510(k) clearance pathway. This mechanism allowed manufacturers to sell these devices by claiming they were “substantially equivalent” to older products, some as unrelated as surgical sutures, without ever proving they were safe for the specific, delicate environment of the breast.
If you are experiencing persistent pain, late-onset swelling, redness, or a hardening of the breast years after your surgery, you are not alone, and your symptoms are not “just part of the healing process.” We are here to help you understand the science of why these devices fail, the laws that protect your rights in Arkansas, and the path toward holding multi-billion-dollar manufacturers like Becton Dickinson (BD) and Allergan accountable. Our managing partner, Ralph Manginello, has spent twenty-seven years fighting for the rights of the injured, licensed by the State Bar of Texas (Bar Card Number 24007597) and admitted to practice in the United States District Court for the Southern District of Texas. Together with associate attorney Lupe Peña, who provides full, fluent Spanish-language consultations, we prosecute high-profile institutional liability cases, including our current representation in Bermudez v. Pi Kappa Phi, a $10,000,000 lawsuit that has garnered national media attention from KPRC 2, ABC13, and KHOU 11. We bring that same level of aggressive, technical litigation to every defective medical device case we handle for the women of Arkansas.
Understanding the Devices: Mesh, ADM, and Scaffolds in Arkansas Breast Surgery
When a surgeon in Little Rock or Jonesboro performs a breast reconstruction or a complex breast lift, they often need a way to support the weight of an implant or the patient’s own tissue. This is often described as an “internal bra” technique. To achieve this, they use one of three primary categories of materials, each now implicated in serious medical complications.
Acellular Dermal Matrix (ADM)
ADM is a biologic material, meaning it is derived from human or animal skin. The manufacturer “decellularizes” the tissue, leaving behind a collagen scaffold that is intended to act as a bridge for your own cells to grow into. Common brands found in Arkansas surgical suites include AlloDerm (Allergan/AbbVie), Strattice (porcine-derived), and FlexHD (MTF Biologics). While marketed as a natural solution, ADM has been linked to elevated rates of “Red Breast Syndrome,” a sterile inflammatory reaction caused by bacterial endotoxins that remain in the tissue even after the manufacturer’s sterilization process.
Bioabsorbable and Resorbable Scaffolds
These are synthetic, man-made materials designed to provide temporary support before eventually dissolving and being absorbed by your body. The most prominent example is GalaFLEX, made by Galatea Surgical and owned by Becton Dickinson. These scaffolds are often composed of poly-4-hydroxybutyrate (P4HB). While the marketing suggests these devices disappear within 18 to 24 months, we have seen cases where the material fails to resorb on schedule, leading to palpable mesh edges, chronic pain, and permanent deformity long after the device should have vanished.
Synthetic Surgical Mesh
Occasionally, permanent synthetic meshes—similar to those used in hernia repairs—are used off-label in breast surgery. These polypropylene products were never designed for the soft tissue of the breast and can lead to aggressive tissue erosion, chronic infection, and the need for catastrophic explantation (removal) of both the mesh and the breast implant.
The FDA Regulatory Failure: Why These Devices Were Never “Approved”
A common misconception among patients at CHI St. Vincent or Mercy Health in Northwest Arkansas is that the FDA “approved” their mesh for breast surgery. High-level legal analysis reveals a much different reality. Under 21 USC §360c and 21 CFR Part 807 Subpart E, most of these devices reached the market through the 510(k) clearance pathway.
Clearance is not approval. In the landmark case Medtronic v. Lohr (518 U.S. 470), the Supreme Court established that 510(k) clearance is a comparative substantial-equivalence finding, not an evaluative determination of safety and effectiveness. Manufacturers essentially “grandfathered” these products into the market by claiming they were similar to “predicate devices.” For instance, the manufacturer of GalaFLEX cited a surgical suture as a predicate. This “predicate creep” meant that a material intended for a tiny stitch was cleared for use as a large internal support structure in the breast without new clinical trials.
The FDA finally addressed this gap on November 9, 2023, in a Letter to Health Care Providers. The agency stated on the record: “The safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA.” The FDA explicitly named the Becton Dickinson (BD) product line—including Phasix and GalaFLEX—as lacking determined safety for breast applications. This admission is a cornerstone of our litigation strategy, as it proves that manufacturers knew, or should have known, that their off-label promotion of these devices was putting women at risk.
The Spectra of Harm: Complications for the Arkansas Patient
If you had reconstruction at a facility like Baptist Health in Little Rock or a cosmetic procedure in the booming Northwest Arkansas corridor, you may be experiencing symptoms that were never disclosed in your informed consent paperwork. We focus on the full range of complications, ensuring that every Arkansas survivor has the medical and legal terminology needed to speak with her physician and her counsel.
BIA-ALCL: The Textured Implant Cancer
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a CD30-positive, ALK-negative T-cell lymphoma. While it is a cancer of the immune system and not the breast tissue itself, it develops in the scar tissue (capsule) surrounding the implant. The World Health Organization (WHO) formally recognized it as a distinct malignancy in 2016. The risk is heavily associated with textured-surface implants, particularly the Allergan BIOCELL line, which was recalled in July 2019. If you have developed a late-onset seroma (fluid collection) seven to ten years after your surgery, this must be ruled out through CD30 immunohistochemistry.
BIA-SCC: An Emerging Threat
The FDA issued a safety communication in September 2022 regarding Breast Implant-Associated Squamous Cell Carcinoma (BIA-SCC). This epithelial tumor is distinct from BIA-ALCL and has been found in the capsules of both textured and smooth implants. Though rarer, it is often more aggressive.
Red Breast Syndrome (RBS)
Unique to acellular dermal matrix (ADM) products like AlloDerm and FlexHD, Red Breast Syndrome presents as a persistent, non-infectious redness of the skin over the implanted matrix. Unlike a typical infection, it does not respond to antibiotics. Peer-reviewed research, including the Nguyen et al. study, points to an endotoxin-mediated mechanism. The manufacturer’s cleaning process may leave behind “ghost” bacterial fragments that trigger a chronic, sterile immune response in your body.
Mechanical and Structural Failures
Bioabsorbable scaffolds like GalaFLEX are marketed to provide “the strength of a permanent mesh with the safety of a resorbable.” However, when these scaffolds fail to degrade correctly—or when they degrade too quickly before the tissue is ready—the results are devastating. We represent women who have experienced:
- Mesh Migration: The scaffold shifts, causing the breast to “bottom out” or move toward the armpit (lateral displacement).
- Tissue Erosion: The sharp edges of a synthetic mesh or an unresorbed scaffold wear through the skin from the inside out.
- Capsular Contracture: The body forms a thick, painful wall of scar tissue (Baker Grade III/IV) in response to the foreign material.
The Whistleblower: Dr. Hooman Noorchashm’s Allegations
One of the most powerful tools in our investigative arsenal is the record of Dr. Hooman Noorchashm. A cardiothoracic surgeon and former Medical Director at Becton Dickinson (BD), Dr. Noorchashm was terminated in 2022 after raising internal alarms about the safety of GalaFLEX. He has publicly alleged that BD withheld data regarding breast cancer recurrences in patients who received GalaFLEX and failed to properly report adverse events to the FDA’s MAUDE database.
When a manufacturer prioritizes profit over the safety of women in Arkansas, they must be held to account. We incorporate these whistleblower facts to pierce the corporate veil that manufacturers often use to hide their knowledge of device defects.
Arkansas Law and Your Rights: Statutes of Limitations and Repose
Time is a critical factor in product liability litigation. Under Arkansas Code § 16-116-103, there is a three-year statute of limitations for personal injury claims arising from a defective product. This clock typically begins to run when you discover, or reasonably should have discovered, the link between your injury and the device.
However, Arkansas also has a ten-year statute of repose. This is an absolute deadline that bars most claims ten years after the date the product was first sold, regardless of when your injury was discovered. Because many breast-mesh and BIA-ALCL symptoms take seven to ten years to manifest, women in Little Rock, Fort Smith, and Fayetteville must act the moment they suspect a problem.
Furthermore, we navigate the “Learned Intermediary Doctrine” in Arkansas. Manufacturers often argue they are not liable because they warned your surgeon (the learned intermediary) instead of you. We counter this by identifying “Parallel Claims”—showing that the manufacturer violated federal FDA requirements (like the duty to report adverse events under 21 CFR Part 803), which bypasses certain preemption defenses established in cases like Riegel v. Medtronic (552 U.S. 312).
Identifying the Culprit: How to Know What Was Used in Your Surgery
Many women reading this in Arkansas may not know if they have “mesh” or “ADM” in their bodies. Surgeons often use these terms interchangeably or describe them simply as “tissue support.” To build a case, we need to identify the specific brand and lot number. We recommend taking these three steps immediately:
- Request Your Operative Report: This is the detailed narrative your surgeon wrote after your procedure. It is available through the medical records department of the hospital (such as UAMS, Mercy, or Baptist Health) where your surgery took place.
- Look for Implant Stickers: Hospitals are required to retain “implant logs.” These often contain the Unique Device Identifier (UDI) sticker with the brand name (e.g., GalaFLEX, AlloMax, Strattice) and the specific lot number.
- Review Your Patient Portal: Modern health systems in Northwest Arkansas and Little Rock often list “implanted devices” in the surgical results section of their online portals.
If you are met with resistance from a hospital or clinic, call us at 1-888-ATTY-911. We have the resources to secure the records you are entitled to by law.
Why The Manginello Law Firm (Attorney911) for Arkansas Cases?
When you are facing a multi-billion-dollar manufacturer like Becton Dickinson or Allergan, you cannot rely on a generalist lawyer who handles simple fender-benders. You need a trial firm with complex litigation experience and a verifiable record of holding massive institutions accountable.
Our managing partner, Ralph Manginello, brings twenty-seven years of continuous practice to your side. His credentials include an Avvo Rating of 8.2 (Excellent) and a Martindale-Hubbell Preeminent 5.0 of 5.0 rating. We are not a settlement farm; we are a trial-ready firm. Our leadership in the Bermudez v. Pi Kappa Phi litigation proves our ability to handle multi-defendant, high-stakes cases that require deep investigation.
Furthermore, our associate attorney, Lupe Peña, is a third-generation Texan with deep roots in our region and is admitted to the United States District Court for the Southern District of Texas. Lupe conducts full, fluent Spanish-language consultations. For the growing Spanish-speaking community in Arkansas—particularly in the River Valley and Northwest Arkansas—we offer a bridge to justice without the need for third-party interpreters. Hablamos español.
We operate on a contingency fee basis. This means there is no upfront cost to you, and we pay for the expensive expert witnesses, medical record reviews, and filing fees required to prosecute a device injury case. We only get paid if we recover money for you. This aligns our interests perfectly with yours: we fight to maximize your recovery because we believe in the merit of your case.
Frequently Asked Questions for Arkansas Survivors
Is it too late to file if my surgery was five years ago?
In most cases, no. While Arkansas has a three-year statute of limitations, the “Discovery Rule” often applies. If you only recently learned that your chronic pain or seroma was linked to a defective device—perhaps because of the FDA’s November 2023 warning—your clock may have just started. However, the ten-year statute of repose is an absolute bar, so you must call a lawyer the moment you suspect a problem.
I don’t want to sue my surgeon. Can I just sue the manufacturer?
Yes. Most of our breast mesh and ADM cases are product liability suits against the manufacturers (like BD or Allergan) for design defects and failure to warn. We focus on the companies that sold these devices for off-label use without adequate testing. While we can evaluate surgical errors, many of our clients maintain excellent relationships with their reconstructive surgeons while pursuing the manufacturer for the defect in the product itself.
What is my case worth?
Every case is unique. However, in the broader mesh litigation world, we see a wide range of settlements. In the pelvic mesh aggregate, over $8 billion was paid to over 100,000 women. In Oct 2024, Becton Dickinson (the maker of GalaFLEX) agreed to settle approximately 38,000 hernia mesh claims for an estimated $1 billion. Individual recoveries for the loss of a breast reconstruction, multiple revision surgeries, and permanent disfigurement can reach significant six- and seven-figure amounts depending on the severity of the harm.
Does health insurance cover the removal of defective mesh?
Under the Women’s Health and Cancer Rights Act of 1998 (WHCRA), if you are a breast cancer survivor, your health plan is required to cover the treatment of complications from your mastectomy and reconstruction. This includes the removal and salvage of failed mesh or ADM. We can help you navigate insurance denials while also pursuing the manufacturer for the damages insurance doesn’t cover, such as pain, suffering, and permanent scarring.
A Path to Recovery in the Natural State
If you are reading this from your home in Jonesboro, a hospital room in Little Rock, or a recovery suite in Rogers, please know that the pain and confusion you feel are valid. You were likely told that these scaffolds and matrices were the “gold standard” of modern surgery. You were not told they were being used off-label, that they were cleared through a regulatory shortcut, or that they carried a doubled risk of infection.
We invite you to reach out to us at 1-888-ATTY-911 (1-888-288-9911) for a free, confidential consultation. There is no obligation, and no salesperson will pressure you. You will speak with a team that understands the pathology of CD30+ lymphoma, the kinetics of P4HB hydrolysis, and the aggressive tactics used by device-manufacturer defense counsel.
Justice for Arkansas survivors begins with the courage to ask what really happened during your surgery. We are here to provide the answers and the advocacy you deserve. Call us today, and let us help you take back your future.
Contact Attorney911
Principal Office: 1177 West Loop South, Suite 1600, Houston, Texas 77027
Toll-Free: 1-888-ATTY-911 (1-888-288-9911)
Hablamos Español. Lupe Peña and our dedicated staff are ready to serve the Spanish-speaking community across Arkansas.
The Manginello Law Firm, PLLC is a Texas-based law firm that handles medical device and catastrophic injury litigation on a national scale. Cases may be handled in association with locally licensed counsel in Arkansas to ensure full compliance with state rules.
